Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - Provectus Pharmaceuticals, Inc. (PVCT-OCT: BB) |
|
|
We have solved the essential problem that other scientists and companies have not been able to solve; that is to make a cancer specific drug. We have found out how to make it simply, pragmatically and inexpensively; namely, to build it and make a very safe molecule. - Dr. H. Craig Dees, Ph.D. (PVCT) (Interview published April 12, 2007) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
Provectus News Phase 2 Data on
Provectus's PV-10 To Be Presented at the 2010 ASCO Scientific
Program on June 4 - 8 in Chicago Provectus announced today that data from its Phase 2 study of PV-10 for metastatic melanoma has been accepted for presentation at the 2010 American Society of Clinical Oncology (ASCO) Scientific Program to be held on June 4 – 8, 2010 in Chicago, Illinois. Dr. Sanjiv Agarwala, Chief, Medical Oncology and Hematology at St. Luke's Hospital and Health Network in Bethlehem, PA, and Principal Investigator for Provectus's Phase 2 PV-10 trial site at St. Luke's, will present Abstract #8534, entitled "Chemoablation of metastatic melanoma with rose bengal (PV-10)," in the General Poster Session. Dr. Agarwala said, "With enrollment of all 80 subjects this multi-center Phase 2 trial completed in May 2009, I look forward to presenting a comprehensive update on PV-10 for treatment of metastatic melanoma. As I recently noted, PV-10 is intriguing to me as an oncologist because it appears to recruit immune cells to the ablation site, leading to the potential of a systemic benefit."
The complete press release is available at Provectus' website at:
|
|
